S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:HRTX

Heron Therapeutics (HRTX) Stock Price, News & Analysis

$2.77
+0.03 (+1.09%)
(As of 03/28/2024 ET)
Today's Range
$2.67
$2.81
50-Day Range
$2.09
$3.06
52-Week Range
$0.50
$3.22
Volume
1.10 million shs
Average Volume
2.93 million shs
Market Capitalization
$416.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Heron Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
80.5% Upside
$5.00 Price Target
Short Interest
Bearish
16.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.63mentions of Heron Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.22) to ($0.09) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.89 out of 5 stars

Medical Sector

245th out of 939 stocks

Pharmaceutical Preparations Industry

111th out of 444 stocks

HRTX stock logo

About Heron Therapeutics Stock (NASDAQ:HRTX)

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

HRTX Stock Price History

HRTX Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
HRTX Apr 2024 1.500 call
Heron Therapeutics Soars After 4Q Earnings Beat
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Q4 2023 Heron Therapeutics Inc Earnings Call
What Wall Street expects from Heron Therapeutics's earnings
Preview: Heron Therapeutics's Earnings
HRTX Mar 2024 0.500 call
See More Headlines
Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/23/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HRTX
Employees
203
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+80.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-110,560,000.00
Pretax Margin
-87.02%

Debt

Sales & Book Value

Annual Sales
$127.04 million
Book Value
($0.23) per share

Miscellaneous

Free Float
140,708,000
Market Cap
$416.41 million
Optionable
Optionable
Beta
1.68

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Craig Alexander Collard (Age 58)
    CEO & Director
  • Ms. Ira Duarte (Age 55)
    Executive VP & CFO
  • Ms. Lisa Peraza (Age 47)
    VP & Chief Accounting Officer
    Comp: $474.1k
  • Dr. Thomas B. Ottoboni Ph.D. (Age 65)
    Chief Scientific Officer and Senior VP of Pharmaceutical & Translational Sciences
  • Mr. Ryan Craig
    Vice President of Marketing
  • Mr. Sean T. Ristine (Age 54)
    Senior Vice President of Human Resources
  • Dr. Chris M. Storgard (Age 58)
    Chief Medical Officer
  • Mr. Robert Sullivan (Age 46)
    Senior VP of Oncology Care Franchise & Commercial Operations
  • Dr. William P. Forbes Pharm. D. (Age 62)
    Pharm.D., Executive VP & Chief Development Officer
  • Jeff Cohn
    Executive Director, Assistant General Counsel & Assistant Secretary

HRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Heron Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings
or view top-rated stocks.

What is Heron Therapeutics' stock price target for 2024?

2 equities research analysts have issued 1 year price objectives for Heron Therapeutics' shares. Their HRTX share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 80.5% from the stock's current price.
View analysts price targets for HRTX
or view top-rated stocks among Wall Street analysts.

How have HRTX shares performed in 2024?

Heron Therapeutics' stock was trading at $1.70 on January 1st, 2024. Since then, HRTX shares have increased by 62.9% and is now trading at $2.77.
View the best growth stocks for 2024 here
.

When is Heron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HRTX earnings forecast
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) issued its earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08. The biotechnology company earned $30 million during the quarter, compared to analysts' expectations of $27.24 million. The business's revenue was up 44.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.54) EPS.

What ETFs hold Heron Therapeutics' stock?

ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD) and Invesco Nasdaq Future Gen 200 ETF (QQQS).Simplify Propel Opportunities ETF (SURI).

What guidance has Heron Therapeutics issued on next quarter's earnings?

Heron Therapeutics issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $138.0 million-$158.0 million, compared to the consensus revenue estimate of $139.1 million.

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.56%), Vanguard Group Inc. (5.56%), Franklin Resources Inc. (4.27%), Palisade Capital Management LP (2.43%), JW Asset Management LLC (1.53%) and Orchard Capital Management LLC (1.49%). Insiders that own company stock include Adam Morgan, Craig A Collard, Craig A Johnson, Ira Duarte, Kimberly Manhard, Waage Christian and William P Forbes.
View institutional ownership trends
.

How do I buy shares of Heron Therapeutics?

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Heron Therapeutics have any subsidiaries?
The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..
Read More
This page (NASDAQ:HRTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners